Thomas C. Hamilton
#152,017
Most Influential Person Now
Thomas C. Hamilton's AcademicInfluence.com Rankings
Thomas C. Hamiltonbiology Degrees
Biology
#11428
World Rank
#14822
Historical Rank
Molecular Biology
#1757
World Rank
#1786
Historical Rank
Biochemistry
#1885
World Rank
#2026
Historical Rank
Download Badge
Chemistry Biology
Thomas C. Hamilton's Degrees
- PhD Biochemistry University of California, San Francisco
- Bachelors Chemistry Stanford University
Why Is Thomas C. Hamilton Influential?
(Suggest an Edit or Addition)Thomas C. Hamilton's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. (1992) (900)
- AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. (1992) (759)
- Platinum Resistance: The Role of DNA Repair Pathways (2008) (702)
- Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. (1985) (585)
- Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. (1983) (545)
- Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. (1987) (524)
- Comparison of the effects of BRL 34915 and verapamil on electrical and mechanical activity in rat portal vein (1986) (438)
- Reversal of adriamycin resistance by verapamil in human ovarian cancer. (1984) (417)
- Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. (1987) (411)
- Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. (1985) (338)
- Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. (2003) (332)
- Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. (2003) (325)
- The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. (1998) (320)
- Focus on epithelial ovarian cancer. (2004) (304)
- Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. (1988) (298)
- Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. (1996) (279)
- Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. (2000) (274)
- The biology of ovarian cancer. (1998) (271)
- Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. (1984) (267)
- Cromakalim, nicorandil and pinacidil: novel drugs which open potassium channels in smooth muscle. (1989) (234)
- Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione. (1987) (220)
- Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. (1995) (191)
- Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. (1992) (190)
- RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. (2007) (187)
- Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches. (1984) (182)
- Advanced epithelial ovarian cancer: 1998 consensus statements. (1999) (180)
- Metallothionein gene expression and resistance to cisplatin in human ovarian cancer (1990) (179)
- Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. (1984) (179)
- Genes amplified and overexpressed in human multidrug-resistant cell lines. (1988) (173)
- Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. (1997) (172)
- Disabled-2 is essential for endodermal cell positioning and structure formation during mouse embryogenesis. (2002) (172)
- Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. (1989) (171)
- Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. (1988) (169)
- Identification of two candidate tumor suppressor genes on chromosome 17p13.3. (1996) (158)
- Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. (1996) (156)
- Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells (2005) (152)
- The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel. (2000) (145)
- Synthesis and antihypertensive activity of 4-(cyclic amido)-2H-1-benzopyrans. (1986) (144)
- Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells. (1994) (138)
- Activation of cancer-specific gene expression by the survivin promoter. (2002) (138)
- Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. (1993) (135)
- AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells. (1998) (134)
- Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. (1994) (129)
- Identification of a gene containing zinc-finger motifs based on lost expression in malignantly transformed rat ovarian surface epithelial cells. (1997) (122)
- The biology of ovarian cancer development (2010) (121)
- Inhibition by glibenclamide of the vasorelaxant action of cromakalim in the rat (1989) (120)
- Expression of insulin-like growth factor I, its binding proteins, and its receptor in ovarian cancer. (1991) (119)
- Mechanisms of drug resistance in ovarian cancer (2010) (116)
- LOT1 (PLAGL1/ZAC1), the Candidate Tumor Suppressor Gene at Chromosome 6q24–25, Is Epigenetically Regulated in Cancer* (2003) (115)
- Ovarian cancer biology. (1991) (115)
- Mechanisms and modulation of resistance to chemotherapy in ovarian cancer (1993) (113)
- Spontaneous transformation of rat ovarian surface epithelial cells results in well to poorly differentiated tumors with a parallel range of cytogenetic complexity. (1994) (110)
- Identification of a zinc-finger gene at 6q25: a chromosomal region implicated in development of many solid tumors (1997) (110)
- Clinical studies of reversal of drug resistance based on glutathione. (1998) (105)
- Adriamycin accumulation and metabolism in adriamycin-sensitive and -resistant human ovarian cancer cell lines. (1986) (103)
- Autonomy of the epithelial phenotype in human ovarian surface epithelium: Changes with neoplastic progression and with a family history of ovarian cancer (1996) (102)
- Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. (1995) (101)
- Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. (1992) (101)
- Estrogen and Anti‐Estrogen Effects on the Growth of Human Epithelial Ovarian Cancer In Vitro (1989) (94)
- Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule. (1994) (94)
- Strategies for high-resolution imaging of epithelial ovarian cancer by laparoscopic nonlinear microscopy. (2010) (93)
- BRL 34915, a novel antihypertensive agent: comparison of effects on blood pressure and other haemodynamic parameters with those of nifedipine in animal models. (1986) (92)
- Synthesis and antihypertensive activity of 6,7-disubstituted trans-4-amino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ols. (1983) (91)
- Anomalous expression of epithelial differentiation-determining GATA factors in ovarian tumorigenesis. (2003) (89)
- Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive dithiolethione oltipraz. (1996) (88)
- Ovarian cancer, Part I: Biology. (1992) (86)
- Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat. (1996) (84)
- Anti-transferrin receptor antibody linked to Pseudomonas exotoxin as a model immunotoxin in human ovarian carcinoma cell lines. (1985) (83)
- A comparison of clonogenic, microtetrazolium and sulforhodamine B assays for determination of cisplatin cytotoxicity in human ovarian carcinoma cell lines. (1993) (81)
- Multidrug resistance in ovarian cancer (1987) (81)
- Characterization of immunotoxins active against ovarian cancer cell lines. (1985) (81)
- Resistance to alkylating agents and cisplatin: insights from ovarian carcinoma model systems. (1990) (79)
- Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies (2003) (76)
- Glutathione and drug resistance. (1996) (76)
- Molecular events associated with dysplastic morphologic transformation and initiation of ovarian tumorigenicity (2002) (74)
- Characterization of a Carcinogenesis Rat Model of Ovarian Preneoplasia and Neoplasia (2004) (71)
- Recent insights into platinum drug resistance in cancer. (1998) (70)
- Transcriptional activation of c-myc proto-oncogene by estrogen in human ovarian cancer cells (1994) (68)
- Cross-resistance, cisplatin accumulation, and platinum-DNA adduct formation and removal in cisplatin-sensitive and -resistant human hepatoma cell lines. (1996) (67)
- Dynamic alterations of the extracellular environment of ovarian surface epithelial cells in premalignant transformation, tumorigenicity, and metastasis (2002) (67)
- Androgen and oestrogen binding in cytosols of human ovarian tumours. (1981) (65)
- Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer. (2004) (64)
- Antitumor activity of an immunotoxin in a nude mouse model of human ovarian cancer. (1987) (62)
- Advanced epithelial ovarian cancer (1999) (60)
- LOT1 is a growth suppressor gene down-regulated by the epidermal growth factor receptor ligands and encodes a nuclear zinc-finger protein (1999) (57)
- Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer (2007) (56)
- Gracile nucleus absent in adult opossums after leg removal in infancy. (1972) (54)
- Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo. (1994) (53)
- TALC IN NORMAL AND MALIGNANT OVARIAN TISSUE (1979) (50)
- Comparative effects of K+ channel blockade on the vasorelaxant activity of cromakalim, pinacidil and nicorandil. (1988) (50)
- Expression of two mucin antigens in cultured human ovarian surface epithelium: Influence of a family hostory of ovarian cancer (1995) (49)
- Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel. (1996) (47)
- Vascular endothelial growth factor in ovarian cancer (1999) (47)
- Decreased expression of retinol-binding proteins is associated with malignant transformation of the ovarian surface epithelium. (2002) (46)
- Cromakalim, a Potassium Channel Activator: A Comparison of its Cardiovascular Haemodynamic Profile and Tissue Specificity with those of Pinacidil and Nicorandil (1988) (45)
- Comparative cytotoxicity of CI‐973, cisplatin, carboplatin and tetraplatin in human ovarian carcinoma cell lines (1991) (45)
- Loss of cellular retinol-binding protein 1 gene expression in microdissected human ovarian cancer. (2003) (44)
- The role of glutathione in drug resistance. (1990) (43)
- Telomeric instability and reduced proliferative potential in ovarian surface epithelial cells from women with a family history of ovarian cancer. (1999) (41)
- Ovarian epithelial cell lineage-specific gene expression using the promoter of a retrovirus-like element. (2001) (41)
- Mechanisms of cross-resistance between radiation and antineoplastic drugs. (1988) (41)
- Differential expression of c-fos, Hsp70 and Hsp27 after photothrombotic injury in the rat brain. (1997) (40)
- Mechanisms of resistance to cisplatin and alkylating agents. (1989) (40)
- Reversal of cisplatin resistance in human ovarian cancer cell lines by a c-jun antisense oligodeoxynucleotide (ISIS 10582): evidence for the role of transcription factor overexpression in determining resistant phenotype. (2002) (40)
- Disabled-2 Mediates c-Fos Suppression and the Cell Growth Regulatory Activity of Retinoic Acid in Embryonic Carcinoma Cells* (2001) (40)
- Serial determinations of glutathione levels and glutathione-related enzyme activities in human tumor cells in vitro. (1986) (38)
- Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment. (1993) (38)
- Growth regulation of ovarian cancer. (1992) (37)
- Effects of Isradipine, an L-Type Calcium Channel Blocker on Permanent and Transient Focal Cerebral Ischemia in Spontaneously Hypertensive Rats (1997) (37)
- Effect of intracerebroventricular 5,6-dihydroxytryptamine on blood pressure of spontaneously hypertensive rats. (1976) (37)
- Motor dysfunction in a photothrombotic focal ischaemia model (1996) (37)
- Expression of two mucin antigens in cultured human ovarian surface epithelium: influence of a family history of ovarian cancer. (1996) (36)
- Somatotopic organization related to nuclear morphology in the cuneate-gracile complex of opossums Didelphis marsupialis virginiana. (1973) (34)
- Effects of talc on the rat ovary. (1984) (34)
- Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO. (1995) (34)
- Expression of Activated PIK3CA in Ovarian Surface Epithelium Results in Hyperplasia but Not Tumor Formation (2009) (33)
- Adoptive cellular immunotherapy of human ovarian carcinoma xenografts in nude mice. (1986) (33)
- Effects of synthetic peptides and protease inhibitors on the interaction of a human ovarian cancer cell line (NIH:OVCAR-3) with a reconstituted basement membrane (Matrigel). (1991) (32)
- Antihypertensive and haemodynamic properties of the potassium channel activating (-) enantiomer of cromakalim in animal models. (1991) (32)
- Synthesis and antihypertensive activity of 4-(substituted-carbonylamino)-2H-1-benzopyrans. (1990) (32)
- Retroviral-like sequences specifically expressed in the rat ovary detect genetic differences between normal and transformed rat ovarian surface epithelial cells. (1995) (30)
- Vitamin A metabolism is impaired in human ovarian cancer. (2009) (30)
- Identification of epidermal growth factor-responsive genes in normal rat ovarian surface epithelial cells. (2003) (28)
- Use of a surrogate marker (human secreted alkaline phosphatase) to monitor in vivo tumor growth and anticancer drug efficacy in ovarian cancer xenografts. (2000) (28)
- Neuroprotective effect of recombinant neutrophil inhibitory factor in transient focal cerebral ischaemia in the rat. (1996) (28)
- Collateral susceptibility of adriamycin-, melphalan- and cisplatin-resistant human ovarian tumor cells to bleomycin. (1986) (27)
- Generation of Tumors in Transgenic Mice Expressing the SV40 T Antigen Under the Control of Ovarian-Specific Promoter 1 (2003) (27)
- Quantitative analysis of ciliary and contractile responses during habituation training in Spirostomum ambiguum. (1974) (27)
- Manipulation of Cellular Thiols to Influence Drug Resistance (1988) (27)
- The chemopreventive agent oltipraz stimulates repair of damaged DNA. (1997) (26)
- Molecular and biological factors in the pathogenesis of ovarian cancer. (1993) (26)
- Modulation of glutathione and related enzymes in reversal of resistance to anticancer drugs. (1995) (26)
- The demonstration of the migration of talc from the vagina and posterior uterus to the ovary in the rat. (1986) (26)
- INDUCTION OF PROGESTERONE RECEPTOR WITH 17β-ESTRADI0L IN HUMAN OVARIAN CANCER (1984) (26)
- Clinical reversal of drug resistance in ovarian cancer. (1993) (25)
- Failure of isradipine to reduce infarct size in mouse, gerbil, and rat models of cerebral ischemia. (1995) (24)
- Comparison of the cardiovascular effects of the novel 5-HT(1B/1D) receptor agonist, SB 209509 (VML251), and sumatriptan in dogs. (1997) (24)
- Targeted gene therapy of ovarian cancer using an ovarian-specific promoter. (2002) (24)
- Modulation of induced resistance to adriamycin in two human breast cancer cell lines with tamoxifen or perhexiline maleate (1986) (21)
- Effects of BRL 38227 on neurally‐mediated responses in the guinea‐pig isolated bronchus (1992) (21)
- Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action. (1993) (20)
- β-adrenoceptor blocking drugs and hypertension (1979) (20)
- Oestrogen receptor-like binding in the surface germinal epithelium of the rat ovary. (1982) (20)
- Decreased cisplatin damage-dependent DNA synthesis in cellular extracts of mismatch repair deficient cells. (1999) (20)
- Biologic therapy for the treatment of malignant common epithelial tumors of the ovary (1987) (20)
- INFLUENCE OF ANTI‐HYPERTENSIVE DRUG TREATMENT ON VASCULAR REACTIVITY IN SPONTANEOUSLY HYPERTENSIVE RATS (1975) (19)
- The Effects of SB 206284A, a Novel Neuronal Calcium-Channel Antagonist, in Models of Cerebral Ischemia (1997) (19)
- A reduction of cyclooxygenase 2 gene dosage counters the ovarian morphological aging and tumor phenotype in Wv mice. (2007) (19)
- Genome Scanning Detects Amplification of the Cathepsin B Gene (CtsB) in Transformed Rat Ovarian Surface Epithelial Cells (1999) (19)
- Transformation of rat ovarian epithelial and Rat-1 fibroblast cell lines by RAST24 does not influence cisplatin sensitivity. (1993) (18)
- Growth inhibition and cytotoxicity induced by Bowman-Birk inhibitor concentrate in cisplatin-resistant human ovarian cancer cells. (1998) (17)
- Identification of zinc finger mRNAs using domain-specific differential display. (1996) (17)
- The role of molecular biology in understanding ovarian cancer initiation and progression (2001) (17)
- Intrinsic sympathomimetic activity of β-adrenoceptor blocking drugs at cardiac and vascular β-adrenoceptors (1978) (16)
- Drug resistance, supportive care and dose intensity (1993) (16)
- Presynaptic dopamine receptors mediate the inhibitory action of dopamine agonists on stimulation-evoked pressor responses in the rat. (1982) (16)
- Increased DT-diaphorase expression and cross-resistance to mitomycin C in a series of cisplatin-resistant human ovarian cancer cell lines. (1996) (15)
- Platinum analogues in preclinical and clinical development (1993) (14)
- In vitro interactions between platinum analogues in human ovarian-carcinoma cell lines (2004) (14)
- COMPARISON OF THE ANTI‐HYPERTENSIVE RESPONSE TO β‐ADRENOCEPTOR BLOCKING DRUGS IN INTACT AND ADRENAL‐DEMEDULLATED SPONTANEOUSLY HYPERTENSIVE RATS (1980) (14)
- The effects of some phosphodiesterase inhibitors on the conductance of the perfused vascular beds of the chloralosed cat (1972) (14)
- Potentiation of cisplatin cytotoxicity in human ovarian carcinoma cell lines by trifluoperazine, a calmodulin inhibitor. (1992) (13)
- Pathology of Ovarian Neoplasms in Genetically Modified Mice. (2004) (13)
- Serum CA 125 and survival of mice inoculated with ovarian carcinoma and treated with antiestrogen, estrogen, or progestin. (1987) (12)
- Summary of symposium: Biology and therapy of ovarian cancer. (1991) (12)
- Specific keynote: chemoprevention of ovarian cancer: the journey begins. (2003) (12)
- Translational research in ovarian cancer: a must (2003) (12)
- Spontaneous transformation of the ovarian surface epithelium and the biology of ovarian cancer (1995) (12)
- Induction of progesterone receptor with 17 beta-estradiol in human ovarian cancer. (1984) (12)
- Stereoselective pharmacokinetics of L-buthionine SR-sulfoximine in patients with cancer. (1994) (12)
- High Dose Cisplatin and Drug Resistance: Clinical and Laboratory Correlations (1988) (11)
- PROLONGED EFFECTS OF p‐CHLOROPHENYLALANINE ON THE BLOOD PRESSURE OF CONSCIOUS NORMOTENSIVE AND DOCA/SALINE HYPERTENSIVE RATS (1976) (11)
- Early ovarian cancer: a review of its genetic and biologic factors, detection, and treatment. (1996) (11)
- Behavioral Plasticity in Protozoans (1975) (10)
- Comparison of some effects of paroxetine with amitriptyline on the cardiovascular system in animals. (1986) (10)
- Hypotensive responses following oral adminstration of beta-adrenoceptor blocking drugs to the conscious cat. (1976) (9)
- Potassium channel modulators : pharmacological, molecular and clinical aspects (1992) (9)
- Relative lack of cardiotoxicity of paroxetine in animal models (1989) (9)
- Synthesis and antihypertensive activity of substituted trans-4-amino-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3-ols. (1984) (9)
- Cancer epithelial de l'ovaire (stades evolues): Conference de consensus (1998) (2000) (9)
- Molecular biology of gynecologic malignancies. (1998) (8)
- K+ channel activators, acute glucose tolerance and glibenclamide-induced hypoglycaemia in the hypertensive rat. (1994) (8)
- The Phosphatidylinositol 3-Kinase / AKT Signal Transduction Pathway Plays a Critical Role in the Expression of p 21 WAF 1 / CIP 1 / SDI 1 Induced by Cisplatin and Paclitaxel 1 (2000) (7)
- Basic research: how much do we know, and what are we likely to learn about ovarian cancer in the near future? (1999) (6)
- [Epithelial ovarian cancer (advanced stage): consensus conference (1998)]. (2000) (6)
- Cyclic nucleotides and central cardiovascular control in the conscious cat. (1980) (6)
- Advanced ovarian cancer. Drug resistance, supportive care and dose intensity. (1993) (6)
- Estrogenic regulation and growth factor expression in human ovarian cancer (HOC) in vitro (1989) (6)
- Cellular glutathione levels and sensitivity to radiation and antineoplastic agents in human ovarian cancer. (1988) (6)
- Re: Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. (1999) (5)
- Follicle Depletion Provides a Permissive Environment for Ovarian Carcinogenesis (2016) (5)
- Plasma prolactin concentrations in hypertensive rats (1979) (5)
- Recent insights into drug resistance in ovarian cancer. (2001) (5)
- Drug resistance in ovarian cancer and potential for its reversal (1995) (5)
- Bufuralol, a newβ-adrenoceptor blocking agent (1975) (5)
- New non-cytotoxic approaches to ovarian cancer. (1999) (4)
- Evaluation of in vitro drug screening leads using experimental models of human ovarian cancer. (1992) (4)
- Evidence for the involvement of alpha-adrenoceptor blockade in the antihypertensive action of diazoxide in the renal hypertensive rat. (1975) (4)
- Modification of the vascular response to isoprenaline by cholinomimetic drugs (1971) (4)
- Determinants of cisplatin sensitivity in normal versus spontaneously transformed rat ovarian surface epithelial cells. (1995) (4)
- Glutathione Depletion with Buthionine Sulfoximine: Potential Clinical Applications (1986) (4)
- Chemoprevention of ovarian cancer: The journey begins (2003) (4)
- Comparison of the vasodilator activity of acetylcholine, cholinomimetics and other vasodilators in two vascular beds of the cat. (1974) (4)
- [Natural history of ovarian adenocarcinomas: from epidemiology to experimentation]. (1998) (4)
- Bufuralol, a new beta-adrenoceptor blocking agent in a series of benzofuran-2-ethanolamines. Part 2: pharmacology. (1977) (3)
- Activity of tricyclic nucleoside 5′-phosphate in model systems of human ovarian cancer (2004) (3)
- Modulation of drug resistance in human ovarian cancer: experimental results and clinical applications. (1986) (3)
- Potentiation of cisplatin cytotoxicity in human ovarian carcinoma cell lines by trifluoperazine, a calmodulin inhibitor (1993) (3)
- Effects of BRL38227, salbutamol, and aminophylline, alone and in combination, on plasma potassium and on the heart (1992) (3)
- Phase I trial of buthionine sulfoximine (BSO) in combination with melphalan (1993) (3)
- Estrogen receptor-rich ovarian adenocarcinoma in vitro and OVCAR-3 in vivo bind radio-halogenated moxestrol (R-2858) (1985) (3)
- Discussion: Development of Experimental Models for Ovarian Cancer (2003) (2)
- Comparison of the effects of nabumetone, a new anti‐inflammatory drug, and indomethacin on arachidonic acid‐induced hypotension in the rat (1983) (2)
- Chapter 28 – Molecular Biology and Molecular Genetics of Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (2004) (2)
- Evaluation ofin vitro drug screening leads using experimental models of human ovarian cancer (1992) (2)
- Its Receptor in Ovarian Cancer Expression of Insulin-like Growth Factor I , Its Binding Proteins (2006) (2)
- Salbutamol-induced hypokalaemia and cardiac stimulation: effect of combination with aminophylline or the potassium channel activator lemakalim (BRL38227) (1990) (1)
- beta-Adrenoceptor blocking drugs and hypertension. (1979) (1)
- Preclinical evaluation of aclacinomycin A for the intraperitoneal treatment of human ovarian carcinoma (2004) (1)
- Synthesis and Antihypertensive Activity of 4‐(Substituted‐ Carbonylamino)‐2H‐1‐benzopyrans. (1991) (1)
- Multidrug resistance to alkylating agents and platinum compounds: state of our knowledge. (1990) (1)
- Cyclic nucleotides and central cardiovascular control in the cat [proceedings]. (1978) (1)
- RESULTS Ovarian Preneoplasia and Neoplasia Induced in Rats with DMBA Female Sprague (2004) (0)
- Expression of Insulin-like Growth Factor I , Its Binding Proteins , and Its Receptor in Ovarian Cancer 1 (2006) (0)
- Advances in Brief Ovarian Epithelial Cell Lineage-specific Gene Expression Using the Promoter of a Retrovirus-like Element 1 (2001) (0)
- Hyperaemic responses in two vascular beds of the anaesthetised cat. (1976) (0)
- AKT2, a putative oncogene encoding a member of a novel subfamily of serine-threonine protein kinases, is amplified and overexpressed in human ovarian carcinomas (1992) (0)
- BUFURALOL, A NEW β-ADRENOCEPTOR BLOCKING AGENT (1976) (0)
- Antihypertensive and angiotensin converting enzyme inhibitory activities of a novel dihydrobenzofuran analogue. (1988) (0)
- Development of experimental models for ovarian cancer (2003) (0)
- 10th Biennial Helene Harris Memorial Trust meeting. (2006) (0)
- Antitumor Activity and Biochemical Effects of Aphidicolin Glycinate ( NSC 303812 ) Alone and in Combination with Cisplatin in Vivo 1 (2006) (0)
- Expression of Insulin-like Growth Factor I, Its Binding Proteins, and Its Receptor in Ovarian Cancer1 (2006) (0)
- Benzopyran compounds for treatment of incontinence. (1986) (0)
- Cell Lines-Diamminedichloroplatinum ( II ) in Human Ovarian Cancer cis to Increased DNA Repair as a Mechanism of Acquired Resistance (2006) (0)
- Anomalous expression of GATA factors underlies the loss of Disabled-2 expression and ovarian tumorigenesis (2004) (0)
- Modification by Buthionine Sulfoximine and-resistant Human Ovarian Cancer Cell Lines and Their Radiation Survival Parameters of Antineoplastic Drug-sensitive Updated (2006) (0)
- Intrinsic sympathomimetic activity of beta-adrenoceptor blocking drugs at cardiac and vascular beta-adrenoceptors. (1978) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Thomas C. Hamilton?
Thomas C. Hamilton is affiliated with the following schools:
